RxDoctor Payments DataLook up a doctor →

Leah Triplett, DO

Rheumatology · Charleston, WVNPI 1679500532

Payments from drug & device makers

$19,106in general payments, 2019–2025

Across 990 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$3K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • GSK$893
  • plus $8K from 50 others

What the payments were for

  • Food & beverage$18,89699%
  • Education$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,106 in reported general payments places this provider in the 80th percentile of 26 rheumatology providers in West Virginia.

See all rheumatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$1,861,774
Medicare patients
508
Services billed
56,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab83$800,211
Enbrel MiniEtanercept39$293,969
Orencia ClickjectAbatacept45$252,188
Cosentyx Sensoready (2 Pens)Secukinumab24$178,630
TremfyaGuselkumab12$167,138
Cosentyx Unoready PenSecukinumab19$160,652
Taltz AutoinjectorIxekizumab21$132,201
OtezlaApremilast25$119,629
XeljanzTofacitinib Citrate20$101,659
Enbrel SureclickEtanercept14$101,599
RinvoqUpadacitinib14$92,858
Xeljanz XrTofacitinib Citrate15$85,045
HumiraAdalimumab12$81,410
BenlystaBelimumab18$66,315
Hydroxychloroquine Sulfate754$34,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira, Savella$2,613$189,29238 claims
Johnson & JohnsonTremfya$1,301$167,13812 claims
AmgenOtezla$4,173$119,62925 claims
PfizerXeljanz$1,238$101,65920 claims
GSKBenlysta$893$66,31518 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$48$3,76848 claims
Lilly USA, LLCCymbalta$766$3,15212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 rheumatology providers in West Virginia.

Other rheumatology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →